MODULATION OF RETINOIC ACID RECEPTOR GENE EXPRESSION AND THERAPEUTIC USES THEREOF

摘要

The present invention relates to a therapy, a diagnostic and a research reagent for disease states that respond to the alteration of the expression of gene coding for retinoic acid receptor isoform beta 2 (RAR beta 2). More particularly, the invention relates to the use of antisense oligonucleotides that hybridize to nucleic acid sequences coding for RAR beta 2. The present invention provides compositions and methods for treating patients, suffering from or predisposed to a physical disorder such as proliferative disorders (e.g. benign hyperplastic pre-cancerous lesions, restenosis, psoriasis, cancer and related metastases) in which RAR beta 2 gene is involved.